In a 36‑year‑old female with major depressive disorder (recurrent, mild), anxiety, unspecified psychosis not due to a substance or known physiological condition, severe intellectual disability, and seizure disorder, who is currently prescribed citalopram 10 mg, olanzapine 5 mg and 10 mg, topiramate 25 mg, divalproex (sprinkle) 125 mg, oxcarbazepine 150 mg, zonisamide 25 mg, benztropine 0.5 mg, and cholecalciferol 5,000 IU, which medication is the safest to begin tapering down?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Benztropine is the Safest Medication to Begin Tapering

Benztropine 0.5 mg should be the first medication to taper and discontinue in this patient. This anticholinergic agent is being used to manage extrapyramidal side effects (EPS) from the antipsychotic olanzapine, and guideline evidence supports that anticholinergics should not be used routinely for long-term EPS management 1, 2.

Clinical Reasoning

Why Benztropine First?

Benztropine serves only a symptomatic/side-effect management role rather than treating any of the patient's primary psychiatric or neurological conditions 1. The medication hierarchy for discontinuation follows this principle: medications used to manage side effects of other drugs should be removed first, particularly when the patient has been stabilized 1.

  • No direct therapeutic benefit for core diagnoses: Unlike the other medications, benztropine doesn't treat MDD, anxiety, psychosis, intellectual disability, or seizures
  • Anticholinergics should be time-limited: Guidelines explicitly state these agents should only be used short-term when EPS are acute or severe, and after dose reduction or switching strategies have been attempted 2
  • Lowest risk profile for discontinuation: Stopping benztropine carries minimal risk compared to abruptly stopping seizure medications (which could precipitate status epilepticus) or psychiatric medications (which could cause relapse or withdrawal syndromes)

Critical Safety Considerations

The patient has a seizure disorder with multiple antiepileptic drugs (AEDs) - topiramate, divalproex, oxcarbazepine, and zonisamide. Abruptly discontinuing any AED could precipitate status epilepticus with life-threatening consequences 3. These medications must remain stable during any polypharmacy reduction.

The patient has psychosis requiring antipsychotic treatment. While olanzapine appears duplicated (5 mg + 10 mg = 15 mg total daily), this is treating her unspecified psychosis. Reducing antipsychotic coverage prematurely risks psychotic decompensation 2, 4.

Citalopram 10 mg treats her recurrent MDD. The FDA label warns against abrupt discontinuation due to withdrawal symptoms including anxiety, irritability, confusion, and electric shock-like sensations 5. Depression treatment should continue given her recurrent course.

Tapering Strategy for Benztropine

Gradual taper over 1-2 weeks is appropriate, reducing by 0.25 mg every few days if the patient tolerates it well. Monitor closely for:

  • Emergence or worsening of EPS: dystonia, akathisia, rigidity, tremor
  • Delayed EPS after antipsychotic stabilization: Guidelines note that anticholinergic medication should be maintained well after antipsychotic discontinuation if needed for ongoing EPS management 1

If EPS symptoms emerge during benztropine taper, the options are:

  1. Slow the taper or maintain current benztropine dose
  2. Consider reducing olanzapine dose (though this risks psychotic relapse)
  3. Resume benztropine if symptoms are intolerable

Why Not Other Medications?

Antiepileptic polypharmacy (4 AEDs) is concerning but represents treatment for refractory seizures. Any AED reduction risks breakthrough seizures or status epilepticus - a medical emergency with significant mortality risk. AED adjustments require specialist consultation and should never be the first step in a general deprescribing effort.

Olanzapine reduction would be premature without understanding:

  • Current psychotic symptom control
  • Whether the split dosing (5 mg + 10 mg) serves a specific purpose
  • Risk of psychotic relapse, which significantly impacts quality of life and safety

Citalopram at 10 mg is already a low dose for MDD treatment. Discontinuation would leave recurrent depression untreated, risking relapse with associated morbidity including suicidality 5.

Common Pitfalls to Avoid

  1. Don't discontinue seizure medications without neurology consultation - the four-drug AED regimen suggests difficult-to-control epilepsy
  2. Don't assume benztropine is still needed - many patients continue anticholinergics indefinitely when they may no longer require them 2
  3. Don't taper multiple medications simultaneously - this makes it impossible to identify which change caused any adverse effects
  4. Don't forget to document baseline EPS status before benztropine taper to objectively assess for symptom emergence

Monitoring Plan

After successful benztropine discontinuation, the next medication to consider tapering would depend on:

  • Seizure control: If seizures are well-controlled for 2+ years, AED reduction could be considered with neurology guidance
  • Psychiatric stability: If psychosis remains in remission, gradual olanzapine consolidation/reduction might be appropriate
  • Depression course: Citalopram continuation depends on time in remission and relapse history

The facility's goal of gradual dose reduction (GDR) is appropriate, but must proceed systematically with the safest medication first, which is unequivocally benztropine in this complex polypharmacy case.

References

1
Guideline

practice parameter on the use of psychotropic medication in children and adolescents.

Journal of the American Academy of Child and Adolescent Psychiatry, 2009

Related Questions

What is the appropriate inpatient psychiatric treatment plan, including medication regimen, for a 55‑year‑old man with major depressive disorder with psychotic features, recent persecutory delusions and auditory/visual hallucinations, a history of intermittent clonazepam, diazepam, and zolpidem use, and current medications rosuvastatin and apixaban?
How should I initiate and monitor combined olanzapine and fluoxetine therapy in a patient with major depressive disorder with psychotic features, while managing risks of metabolic side effects and serotonin syndrome?
In a 67-year-old female with depression, schizophrenia, and mood disorder who is currently taking escitalopram 20 mg daily, olanzapine 5 mg twice daily, mirtazapine 30 mg at bedtime, fluphenazine 10 mg twice daily, buspirone 5 mg three times daily, and extended‑release divalproex sodium (Depakote ER) 250 mg twice daily, and whose depression is worsening, what is the appropriate next change in her medication management?
What are the treatment options for a 20‑year‑old patient with depression who feels anxious and zombie‑like after increasing their current medication from 35 mg to 50 mg (after eight months of therapy) and who previously had an unsuccessful trial of fluoxetine (Prozac)?
What is the appropriate initiation, titration, and monitoring plan for bupropion maintenance therapy in a 27-year-old woman with mixed anxiety and depressive disorder?
Can long-term low-dose corticosteroid use cause pruritic blisters on the feet?
In an 84-year-old male who was recently hospitalized after a mechanical fall and had low‑grade methicillin‑resistant Staphylococcus epidermidis (MRSE) and vancomycin‑resistant Enterococcus (VRE) bacteremia that cleared, with a history of MRSE prosthetic knee joint infection on chronic suppressive clindamycin, and a plan for a 2‑week course of daptomycin followed by resumption of clindamycin, should additional blood cultures, laboratory monitoring (complete blood count, comprehensive metabolic panel, creatine kinase) or further workup such as transesophageal echocardiography be performed before restarting chronic clindamycin?
Should ferrous sulfate be discontinued in a 2‑month‑old infant if it causes tooth staining?
What are the possible causes of occasional head spinning (vertigo/ataxia) in a young girl?
What comprehensive information should I know about menopause, including lifestyle measures, hormone therapy options, non‑hormonal treatments, bone health, and monitoring?
Can azithromycin be given together with linezolid in a patient with a skin infection, positive culture, and renal function (GFR ≈ 66 mL/min) receiving linezolid 600 mg every 12 hours?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.